Microarray Patches for Transdermal Drug Delivery

Dear Colleagues,

Nearly 25 years on from the publication of the first paper on microarray patch-mediated drug delivery, the field is now tantalisingly close to achieving a commercial product. The World Economic Forum for instance has listed microarray patches as one of the Top Ten Emerging Technologies in 2020. This is owing to the number of advantages microarray patches can offer over the current routes of drug administration, such as the ability to avoid first-pass metabolism and gastrointestinal degradation, pain-free administration and avoidance of needle-stick injuries common with hypodermic syringes. To date, the transdermal delivery of both small and large molecules for therapeutic applications has been investigated using hollow, coated, dissolving, hydrogel-forming and porous microarray patch designs. Therefore, the aim of this Special Issue is to provide insights into the current and future developments of microarray patch-mediated transdermal drug delivery and how this can truly achieve patient and commercial benefits. In this Special Issue, original research articles and reviews are welcome. Research areas may include (but are not limited to) scalable manufacturing methods to aid commercialisation, delivery of biologics, development approaches to achieve long-acting transdermal drug delivery, end-user considerations and product designs.

We look forward to receiving your contributions.

Dr. Ana Sara Cordeiro
Dr. Aaron Hutton
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.